Orphan Drug Approvals — May 22, 2026
This digest covers 4 label expansion approvals from May 15-20, 2026, with zero NMEs, biosimilars, or first-cycle new indications. All four approvals are classified as 'FALLBACK' type and carry bullish signals of moderate strength (5/10) and materiality (5/10), but lack disclosed commercial data. The dominant therapeutic area is oncology, with three of four approvals targeting cancer indications. The highest-conviction signal is the dual label expansion for Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki), which received two separate approvals on the same day, signaling aggressive lifecycle management and potential market expansion for this blockbuster ADC. A key watch item is the lack of specificity in approval details—without disclosed peak sales, exclusivity, or pricing data, the investment thesis remains opaque and requires follow-up from sponsor disclosures or clinical trial readouts.